Prof. Helge Rasmussen
A novel therapeutic target in pancreatic cancer: Implications for therapy and diagnosis
Grant
A novel therapeutic target in pancreatic cancer: Implications for therapy and diagnosis
Award
2016 Innovation Grant
Institution
University of Sydney
Principal Investigator
Prof. Helge Rasmussen, Chair of Cardiology and Head of the Cardiac Membrane Biology laboratory at the Kolling Institute, University of Sydney/Royal North Shore Hospital, 1997- current
Time required to complete project
1 year
Project Summary
Pancreatic cancers have a very poor prognosis and the project team have discovered that a protein derivative sensitises cancer cells to currently used treatments, potentially making highly treatment-resistant pancreatic cancers responsive to chemotherapy and/or radiotherapy. The augmentation treatment effect by the derivative will be examined in human pancreatic cancers expressed in mice.
Research Reports
Click to download progress reporting on the outcomes of this research.